Among participants who were tested and had normal laboratory values at baseline, the development of thrombocytopenia, anaemia, elevated liver enzymes (AST and ALT) and CKD were not different between the treatment arms at week 24, S3-S8 Tables. This evidence concerns the gene GPT and Thrombocytopenia.